P009 Prediction of AMG 181 pharmacokinetics and pharmacodynamics in humans

P008 Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti a4 b7 antibody for treating inflammatory bowel disease W.-J. Pan1 *, S. Lear2, S. Patel1, P. Prince1, D. Doherty1, C.-Y. Tam1, C. Sheckler1, H. Hsu3, W. Rees2, A. Anderson4, J. Wisler5, K. Reynhardt6, J. Lynch7, J. Brandvig8, L. Wienkers1, D. Borie9. 1Amgen Inc., Pharmacokinetics and Drug Metabolism, Seattle, United States, 2Amgen Inc., Molecular Sciences and Computational Biology, Seattle, United States, 3Amgen Inc., Inflammation, Thousand Oaks, United States, 4Amgen Inc., Molecular Sciences and Computational Biology, Thousand Oaks, United States, 5Amgen Inc., Toxicology, Thousand Oaks, United States, 6Amgen Inc., Clinical Immunology, Seattle, United States, 7Charles River Laboratories, Preclinical Services, Reno, United States, 8Amgen Inc., Toxicology, Seattle, United States, 9Amgen Inc., Inflammation Clinical Research, Thousand Oaks, United States